{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:51:49Z","timestamp":1777870309640,"version":"3.51.4"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chemocentryx"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is associated with end-organ damage resulting in significant morbidity and mortality. Most recently, avacopan, an orally administered selective antagonist of the C5a receptor, was approved by the US Food and Drug Administration as an adjunctive treatment of adult patients with severe, active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy including glucocorticoids. This case study describes a 58-year-old Asian female with severe ANCA-associated vasculitis and acute renal failure who responded to adjunctive therapy with avacopan despite being refractory to rituximab and glucocorticoid therapy.<\/jats:p>","DOI":"10.1007\/s40620-023-01614-y","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T05:03:13Z","timestamp":1681102993000},"page":"2365-2370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-2430","authenticated-orcid":false,"given":"Luis","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraja","family":"Kambham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"issue":"3","key":"1614_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5152\/eurjrheum.2015.0043","volume":"3","author":"C Pagnoux","year":"2016","unstructured":"Pagnoux C (2016) Updates in ANCA-associated vasculitis. Eur J Rheumatol 3(3):122\u2013133","journal-title":"Eur J Rheumatol"},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/jcm10071446","volume":"10","author":"S Almaani","year":"2021","unstructured":"Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D (2021) ANCA-associated vasculitis: an update. J Clin Med 10:1446","journal-title":"J Clin Med"},{"issue":"10","key":"1614_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164646","volume":"11","author":"P Bekker","year":"2016","unstructured":"Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L et al (2016) Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study. PLoS ONE 11(10):e0164646","journal-title":"PLoS ONE"},{"issue":"7","key":"1614_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599\u2013609","journal-title":"N Engl J Med"},{"issue":"9","key":"1614_CR5","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28(9):2756\u20132767","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1614_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A et al (2020) Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol 2(11):662\u2013671","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"1614_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","volume":"7","author":"JR van Leeuwen","year":"2022","unstructured":"van Leeuwen JR, Bredewold OW, van Dam LS, Werkman SL, Jonker JT, Geelhoed M et al (2022) Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 7(3):624\u2013628","journal-title":"Kidney Int Rep"},{"issue":"10","key":"1614_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236236","volume":"13","author":"D Ennis","year":"2020","unstructured":"Ennis D, Yeung RSM, Pagnoux C (2020) Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. BMJ Case Rep 13(10):e236236","journal-title":"BMJ Case Rep"},{"issue":"5","key":"1614_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","volume":"7","author":"C Gabilan","year":"2022","unstructured":"Gabilan C, Pfirmann P, Ribes D, Rigothier C, Chauveau D, Casemayou A et al (2022) Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep 7(5):1115\u20131118","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1614_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ekir.2022.10.033","volume":"8","author":"S Hakroush","year":"2023","unstructured":"Hakroush S, Tampe B (2022) Tailored use of avacopan in a case with refractory antineutrophil cytoplasmic autoantibody-associated renal vasculitis and concominant complement system activation. Kidney Int Rep 8(2):376\u2013378","journal-title":"Kidney Int Rep"},{"key":"1614_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.854300","volume":"9","author":"X Qin","year":"2022","unstructured":"Qin X, Hu H, Cen J, Wang X, Wan Q, Wei Z (2022) Association between urinary protein-to-creatinine ratio and chronic kidney disease progression: a secondary analysis of a prospective cohort study. Front Med (Lausanne) 9:854300","journal-title":"Front Med (Lausanne)"},{"key":"1614_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926044","volume":"13","author":"Y Kimoto","year":"2022","unstructured":"Kimoto Y, Horiuchi T (2022) The complement system and ANCA associated vasculitis in the era of anti-complement drugs. Front Immunol 13:926044","journal-title":"Front Immunol"},{"issue":"9","key":"1614_CR13","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/eji.201041350","volume":"41","author":"AC Raby","year":"2011","unstructured":"Raby AC, Holst B, Davies J, Colmont C, Laumonnier Y, Coles B et al (2011) TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. Eur J Immunol 41(9):2741\u20132752","journal-title":"Eur J Immunol"},{"issue":"4","key":"1614_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00109-009-0442-7","volume":"87","author":"PA Ward","year":"2009","unstructured":"Ward PA (2009) Functions of C5a receptors. J Mol Med 87(4):375\u2013378","journal-title":"J Mol Med"},{"issue":"3","key":"1614_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.kint.2017.09.018","volume":"93","author":"J Dick","year":"2018","unstructured":"Dick J, Gan PY, Ford SL, Odobasic D, Alikhan MA, Loosen SH et al (2018) C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti- myeloperoxidase glomerulonephritis. Kidney Int Rep 93(3):615\u2013625","journal-title":"Kidney Int Rep"},{"issue":"1","key":"1614_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nep.13747","volume":"26","author":"K Bantis","year":"2021","unstructured":"Bantis K, Stangou M, Kalpakidis S, Hatziadamou M, Daikidou DV, Lioulios G et al (2021) Systemic complement activation in antineutrophil cytoplasmic antibody-associated vasculitis and necrotizing glomerulonephritis. Nephrology (Carlton) 26(1):30\u201337","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"1614_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"SJ Gou","year":"2013","unstructured":"Gou SJ, Yuan J, Chen M, Yu F, Zhao MH (2013) Circulating complement activation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep 83(1):129\u2013137","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1614_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1681\/ASN.2008050497","volume":"20","author":"A Schreiber","year":"2009","unstructured":"Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R (2009) C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 20(2):289\u2013298","journal-title":"J Am Soc Nephrol"},{"issue":"18","key":"1614_CR19","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3390\/ijms20184465","volume":"20","author":"IJ Tsai","year":"2019","unstructured":"Tsai IJ, Lin WC, Yang YH, Tseng YL, Lin YH, Chou CH et al (2019) High concentration of C5a-induced mitochondria-dependent apoptosis in murine kidney endothelial cells. Int J Mol Sci 20(18):4465","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1614_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC (2007) Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52\u201364","journal-title":"Am J Pathol"},{"issue":"6","key":"1614_CR21","doi-asserted-by":"publisher","first-page":"F597","DOI":"10.1152\/ajprenal.00404.2021","volume":"322","author":"RK Sahu","year":"2022","unstructured":"Sahu RK, Xavier S, Chauss D, Wang L, Chew C, Stallcup WB et al (2022) Folic acid-mediated fibrosis is driven by C5a receptor 1-mediated activation of kidney myeloid cells. Am J Physiol Renal Physiol 322(6):F597-610","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"1614_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y et al (2014) C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25(2):225\u2013231","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1614_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/acr2.11412","volume":"4","author":"WD Soulsby","year":"2022","unstructured":"Soulsby WD (2022) Journal club review of \u201cAvacopan for the treatment of ANCA-associated vasculitis.\u201d ACR Open Rheumatol 4(7):558\u2013561","journal-title":"ACR Open Rheumatol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01614-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:52:40Z","timestamp":1777564360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/8\/2365\/8304203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01614-y","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"23 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LA reports consultant fees from ChemoCentryx, a wholly-owned subsidiary of Amgen, Inc. NK and RS have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The case study was conducted ethically in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"This study was performed according to the Declaration of Helsinki. No animals were involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The patient described in this manuscript provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}